Coronavirus vaccine - Zydus Cadila
Latest Information Update: 28 May 2024
At a glance
- Originator Zydus Cadila
- Class Attenuated vaccines; COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Europe (Parenteral)
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in India (Parenteral)
- 04 Jul 2020 Zydus Cadila plans a phase I/II trial in Healthy volunteers in India (Intradermal) (CTRI/2020/07/026352)